All Categories - InBrain Pharma

InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference

22 septembre 2025
Lille, September 22, 2025 – InBrain Pharma, a company specialized in the brain infusion of...

France Parkinson takes a stake in InBrain Pharma, a company developing A-dopamine therapy for brain infusion

22 juillet 2025
Lille,France – 22nd July 2025– InBrain Pharma, a company specialized in brain infusion of...

INBrain Pharma receives EMA Positive Scientific Advice supporting Phase 3 clinical development of A-dopamine for the treatment of advanced Parkinson’s diseasE

3 juillet 2025
Lille, France - July3rd, 2025 - InBrain Pharma, a biopharmaceutical company specializing in...

A GlobalData Insights Investigative News : InBrain Pharma Examines CRO and Pharma Partners to Support Phase III Trial of Lead Parkinson’s Therapy in EU and US

18 juin 2025
- US/EU Phase III trial of A-dopamine in Parkinson’s is set for 2027 - InBrain seeks a CRO or...

InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease

13 mai 2025
InBrain Pharma, a clinical stage biotech specialized in therapeutic solution development against...

A World Premiere in Parkinson’s Disease With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson’s disease management

27 janvier 2025
Lille, January 27, 2025 – InBrain Pharma, a clinical stage biotech specialized in therapeutic...

InBrain Pharma to Present Positive Results from Its DIVE-I Phase I/II Clinical Trial for Parkinson’s Disease at the Congress of Parkinson’s Disease and Movement Disorders from September 27 to October 1 in Philadelphia

25 septembre 2024
Lille, September 25, 2024 - InBrain Pharma, a biopharmaceutical company specialized in...

InBrain Pharma announces the publication of an article on the pharmacokinetic and pharmacodynamic limitations of L-DOPA in the management of Parkinson's disease in the Journal of Parkinson's Disease

12 septembre 2024
InBrain Pharma, a biopharmaceutical company specialized in neurodegenerative disease management,...

European Inventor Award 2024 from the European Patent Office:Professors David Devos and Caroline Moreau, co-founders of InBrain Pharma, selected as finalists in the “Research” category for their therapeutic innovation in Parkinson’s disease

16 mai 2024
InBrain Pharma, a biotech specialized in brain infusion of drugs for neurodegenerative disease...

InBrain Pharma announces the completion of its DIVE-I phase I/II clinical trial in Parkinson's disease

2 mai 2024
InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder...

IInBrain Pharma announces the appointment of Dr Véronique Foutel as CEO

26 février 2024
InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder...

World premiere :A clinical trial allowing direct delivery of dopamine to the brain shows excellent results in treating Parkinson's disease

11 avril 2022
Currently conducted at the Lille University Hospital, DIVE is a revolutionary clinical  trial...

INBRAIN PHARMA OBTAINS ANSM AGREEMENT FOR ITS CLINICAL TRIAL REQUEST

29 mai 2020
InBrain Pharma, a Lille biotechnology start-up developing therapeutic solutions against brain...

New scientific publication

7 avril 2020
Our team is pleased to inform you of the publication of its article concerning the results of...
More Posts
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More